Who Benefits from Treatment of Primary Hyperparathyroidism?

Catherine Y Zhu; Dalena T Nguyen; Michael W Yeh

doi:10.1016/j.suc.2019.04.007

Who Benefits from Treatment of Primary Hyperparathyroidism?

Surg Clin North Am. 2019 Aug;99(4):667-679. doi: 10.1016/j.suc.2019.04.007. Epub 2019 May 11.

Authors

Catherine Y Zhu¹, Dalena T Nguyen², Michael W Yeh²

Affiliations

¹ Section of Endocrine Surgery, Department of Surgery, UCLA David Geffen School of Medicine, 10833 Le Conte Avenue, CHS 72-182, Los Angeles, CA 90095, USA. Electronic address: CatherineZhu@mednet.ucla.edu.
² Section of Endocrine Surgery, Department of Surgery, UCLA David Geffen School of Medicine, 10833 Le Conte Avenue, CHS 72-182, Los Angeles, CA 90095, USA.

PMID: 31255198
DOI: 10.1016/j.suc.2019.04.007

Abstract

Parathyroidectomy (PTx) is the only definitive treatment for primary hyperparathyroidism (PHPT), but is commonly underutilized. Most patients are medically observed, whereas approximately 30% of patients are treated operatively. PTx is a low-risk surgical procedure and the most cost-effective treatment option. An international consensus statement was published in 1990 to guide clinicians in the management of patients with PHPT, particularly those with asymptomatic disease. Most patients with PHPT and low perioperative risk benefit from surgical treatment, regardless of whether they meet consensus criteria, due to fracture risk reduction, health-related quality-of-life improvements, and prevention or mitigation of disease progression.

Keywords: Asymptomatic primary hyperparathyroidism; Endocrine; Hypercalcemia; Parathyroid hormone; Parathyroidectomy.

Publication types

Review

MeSH terms

Consensus*
Humans
Hyperparathyroidism, Primary / surgery*
Parathyroidectomy / methods*
Quality of Life*
Treatment Outcome